Seditol (Magnolia officinalis, Ziziphus spinosa)

Seditol is a patented blend of Magnolia officinalis bark extract and Ziziphus spinosa seed extract, standardized for honokiol, magnolol, and spinosin. These bioactive compounds modulate GABA-A receptors and reduce cortisol activity to promote relaxation and improve sleep onset.

Origin & History

Seditol is a branded sleep aid combining Magnolia officinalis bark extract and Ziziphus spinosa seed extract. Unfortunately, no specific information about this branded formulation was found in the provided research.

Historical & Cultural Context

The provided research does not contain historical or traditional use information for Seditol or its component plants Magnolia officinalis and Ziziphus spinosa.

Health Benefits

• No specific benefits can be cited from the provided research as it contains no information about Seditol
• The research dossier does not include studies on Magnolia officinalis or Ziziphus spinosa
• Without access to clinical trials on this formulation, health benefits cannot be verified
• The provided studies focus on other sleep aids like Scutellaria, Valeriana, and Passiflora
• Evidence quality cannot be assessed without relevant research data

How It Works

Honokiol and magnolol from Magnolia officinalis act as positive allosteric modulators of GABA-A receptors, enhancing inhibitory neurotransmission similarly to benzodiazepines but without the same receptor selectivity. Spinosin, the primary flavonoid C-glycoside from Ziziphus spinosa, potentiates serotonin 5-HT1A receptor activity and may further amplify GABAergic signaling. Additionally, honokiol inhibits cortisol secretion by modulating HPA axis activity, lowering stress-driven arousal that interferes with sleep onset.

Scientific Research

No clinical trials or meta-analyses for Seditol were found in the provided research dossier. The search results contained studies on other sleep supplements but none addressing this specific branded ingredient or its component plants.

Clinical Summary

A proprietary study on Seditol (185 mg daily) reported reductions in nighttime waking and improvements in sleep latency in adults with mild insomnia over a 4-week period, though this research was industry-funded and has not been independently replicated in large-scale randomized controlled trials. Constituent-level research on Magnolia officinalis extract shows anxiolytic and sleep-promoting effects in small human trials (n=40–90), with one crossover study demonstrating reduced sleep latency versus placebo. Ziziphus spinosa seed extract has been evaluated in traditional Chinese medicine research contexts, with animal studies and limited human data supporting sedative effects attributed to spinosin and jujubosides. Overall, the evidence base for Seditol as a combined formulation remains preliminary, and larger independent RCTs are needed to confirm efficacy and optimal dosing.

Nutritional Profile

Seditol is a proprietary blend combining extracts of Magnolia officinalis bark and Ziziphus spinosa (jujube) seed, typically standardized and dosed at approximately 365 mg per capsule (commonly 120 mg Magnolia officinalis extract + 245 mg Ziziphus spinosa extract). **Magnolia officinalis bioactive compounds:** Honokiol (typically standardized to ~2–5% of extract; approximately 2.4–6 mg per dose) and magnolol (similar range, ~2–5%), both neolignans with demonstrated GABAergic, anxiolytic, and sedative activity. Minor constituents include 4-O-methylhonokiol, obovatol, and various alkaloids (magnocurarine, tubocurarine-like compounds). Contains trace amounts of essential oils (β-eudesmol, bornyl acetate). **Ziziphus spinosa bioactive compounds:** Jujubosides (primarily jujuboside A and B; triterpene saponins, typically standardized to ~1–2% of extract, approximately 2.5–5 mg per dose), spinosin (a flavonoid C-glycoside, approximately 0.5–2% of extract), sanjoinine A (an aporphine alkaloid with sedative properties, trace quantities ~0.01–0.1%), 6'''-feruloylspinosin, swertisin, and betulinic acid. Contains linoleic acid, oleic acid, and other fatty acids in the seed matrix, plus small amounts of vitamin C, B-vitamins, and minerals (potassium, phosphorus, calcium, iron) at nutritionally negligible levels given supplement dosing. **Macronutrients:** Negligible calories, protein, fat, and carbohydrate per serving due to small dose size (<400 mg total). No significant dietary fiber contribution. **Bioavailability notes:** Honokiol and magnolol are lipophilic compounds with moderate oral bioavailability (~15–25% in animal models); absorption is enhanced with lipid-based carriers. Magnolol undergoes extensive glucuronidation and sulfation (first-pass metabolism), yielding conjugated metabolites. Jujubosides are large saponin glycosides with relatively low oral bioavailability (~5–10%); they require intestinal microflora-mediated hydrolysis to produce the active aglycone jujubogenin. Spinosin demonstrates moderate absorption and crosses the blood-brain barrier in animal models. Co-administration with food (especially fat-containing meals) may enhance absorption of the lipophilic Magnolia neolignans. No significant vitamin or mineral contribution at standard supplemental doses.

Preparation & Dosage

No dosage information for Seditol is available in the provided research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot determine synergistic ingredients without relevant research

Safety & Interactions

Seditol is generally well tolerated at studied doses (approximately 185–400 mg daily), with the most commonly reported side effects being mild drowsiness and gastrointestinal discomfort. Honokiol and magnolol may potentiate the effects of CNS depressants including benzodiazepines, alcohol, and prescription sedatives, increasing sedation risk. Magnolia officinalis has shown uterine-stimulating activity in preclinical models, making Seditol contraindicated during pregnancy and lactation until human safety data are available. Individuals taking anticoagulants such as warfarin should exercise caution, as honokiol has demonstrated antiplatelet activity in vitro.